These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26948203)

  • 1. Effects of body mass index or dosage on gastrointestinal disorders associated with extended-release metformin in type 2 diabetes: Sub-analysis of a Phase IV open-label trial in Chinese patients.
    Guo L; Guo X; Li Y; Hong X; Jiang X; Su Q; Zhao D; Wu X; Ji L
    Diabetes Metab Syndr; 2016; 10(3):137-42. PubMed ID: 26948203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
    Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
    PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
    Ji L; Liu J; Yang J; Li Y; Liang L; Zhu D; Li Q; Ma T; Xu H; Yang Y; Zeng J; Feng B; Qu S; Li Y; Ma L; Lin S; Wang J; Li W; Song W; Li X; Luo Y; Xi S; Lin M; Liu Y; Liang Z
    Diabetes Obes Metab; 2018 Apr; 20(4):1006-1013. PubMed ID: 29227571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
    Ong CR; Molyneaux LM; Constantino MI; Twigg SM; Yue DK
    Diabetes Care; 2006 Nov; 29(11):2361-4. PubMed ID: 17065668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding and overcoming metformin gastrointestinal intolerance.
    Bonnet F; Scheen A
    Diabetes Obes Metab; 2017 Apr; 19(4):473-481. PubMed ID: 27987248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial.
    Cai H; Chen Q; Duan Y; Zhao Y; Zhang X
    Front Endocrinol (Lausanne); 2023; 14():1106868. PubMed ID: 36777344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center.
    Meyers AG; Hudson J; Cravalho CKL; Matta ST; Villalobos-Perez A; Cogen F; Chung ST
    Pediatr Diabetes; 2021 Mar; 22(2):182-191. PubMed ID: 33179823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: a sub-analysis of data from a randomised clinical trial.
    Zeng Z; Yang JK; Tong N; Yan S; Zhang X; Gong Y; Woerle HJ
    Curr Med Res Opin; 2013 Aug; 29(8):921-9. PubMed ID: 23672632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The magnitude of weight loss induced by metformin is independently associated with BMI at baseline in newly diagnosed type 2 diabetes: Post-hoc analysis from data of a phase IV open-labeled trial.
    Zhou L; Cai X; Yang W; Han X; Ji L
    Adv Clin Exp Med; 2017 Jul; 26(4):671-677. PubMed ID: 28691423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study.
    Hermans MP; Delibasi T; Farmer I; Lohm L; Maheux P; Piatti P; Malvolti E; Jörgens S; Charbonnel B
    Curr Med Res Opin; 2012 Oct; 28(10):1635-45. PubMed ID: 23020253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the phenotype of patients with gastrointestinal intolerance to metformin?
    Hermans MP; Ahn SA; Rousseau MF
    Diabetes Metab; 2013 Sep; 39(4):322-9. PubMed ID: 23786968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
    Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
    Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Asymptomatic chronic gastritis decreases metformin tolerance in patients with type 2 diabetes.
    Huang Y; Sun J; Wang X; Tao X; Wang H; Tan W
    J Clin Pharm Ther; 2015 Aug; 40(4):461-5. PubMed ID: 26032654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Appropriate insulin initiation dosage for insulin-naive type 2 diabetes outpatients receiving insulin monotherapy or in combination with metformin and/or pioglitazone.
    Liao L; Yang M; Qiu LL; Mou YR; Zhao JJ; Dong JJ
    Chin Med J (Engl); 2010 Dec; 123(24):3684-8. PubMed ID: 22166651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.